<P>tulane.edu/som TULANE | MEDICINE FALL 2013 3 P atients ?ghting prostate cancer have a new treatment option on the market, thanks in part to a major clinical trial led by Tulane University cancer specialist Dr. Oliver Sartor. The U.S. Food & Drug Administration recently approved radium-223 dichloride (Xo?go®) for the treatment of men with symptomatic, bone-metastatic, castration-resistant prostate cancer that has spread to the bones but not to other organs. This is an important addition to the treatment of advanced prostate cancer, says Sartor, Tulane Cancer Center medical director and North American principal investigator for the pivotal phase III clinical trial of the drug. It is immensely satisfying to be part of something that helps move medicine forward and provides new treatments to those who need it most. About the study: Patients from Seattle to Florida were treated at Tulane, which was the leading trial site in North America. The trial involved 921 patients—in more than 100 centers in 19 countries—who were randomly assigned to radium-223 or a placebo plus best standard of care. Most men with castration-resistant prostate cancer develop bone metastases, which can decrease overall survival, Sartor says. About the drug: Radium-223 is an alpha particle-emitting radioactive therapeutic agent that seeks out regions of the bone affected by metastatic tumors. This allows delivery of radiation directly to tumors TULANE MAJOR PLAYER IN FDA APPROVAL OF NEW DRUG FOR ADVANCED PROSTATE CANCER and limits damage to the surrounding normal tissues. It is administered via injection. Trial results showed that men receiving radium-223 lived a median of 14.9 months compared to a median of 11.3 months for those receiving a placebo. Radium-223 was approved more than three months ahead of schedule under the FDAs priority review program, which expedites the review of drugs that appear to provide safe and effective therapy when no satisfactory alternative exists, or that offer signi?cant improvement compared to existing treatments. The commercial production of radium-223 is being co-marketed by Bayer and Algeta. A frican-Americans with hepatitis C who are undergoing liver transplants have better outcomes when theyre matched with black donors, according to a new study led by Tulane University liver specialist Dr. Nathan Shores. For years, doctors have found that African-American hepatitis C liver transplant patients have poorer outcomes and lower 5-year survival rates compared to other racial groups. However, doctors dont consider the donors race or the recipients hepatitis status in evaluating whether a donated organ will survive in a potential transplant patient. Shores and researchers from the University of California– San Francisco analyzed data for more than 1,750 hepatitis C positive African-American patients to more accurately determine transplant risks for black patients. Surprisingly, the ?ndings showed that when racially matched, black patients had long-term survival rates closer to those of other groups. It turns out that having a black liver is so powerful for a black patient with hepatitis C that, if they do get such a liver, doctors can use a much older liver (than previously thought possible), and theyll live much longer, says Shores, assistant professor of clinical medicine at Tulane University School of Medicine. FOR AFRICAN-AMERICANS, DONOR RACE A CRITICAL FACTOR IN LIVER TRANSPLANT SUCCESS Tulane University liver specialist Dr. Nathan Shores hopes the study encourages more minority organ donors. Genetic differences in immune response to hepatitis C could explain the difference in outcomes, but further study is needed, Shores says. His new risk model showed that study patients did best when the liver was from a black donor, a young donor and there was very little cooler time for the organ prior to transplantation. The study, which will be published in Hepatology, underscores the need for more minority organ donors. African-Americans comprised only 14 percent of organ donors last year, yet 29 percent of those waiting for transplants are black, according to the federal Of?ce of Minority Health. If more African-Americans become donors in areas that have a lot of minority patients, its possible that they could help others who are at such a disadvantage when it comes to transplant survival, Shores says. </p> <UL><LI><a href="http://www.mzines.net/publication/297/wqtaigylu/1/1/">Front-Cover</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/2/2/">Inside-Front-Cover</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/3/3/">Page-3</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/4/4/">Page-4</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/5/5/">Page-5</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/6/6/">Page-6</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/7/7/">Page-7</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/8/8/">Page-8</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/9/9/">Page-9</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/10/10/">Page-10</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/11/11/">Page-11</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/12/12/">Page-12</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/13/13/">Page-13</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/14/14/">Page-14</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/15/15/">Page-15</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/16/16/">Page-16</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/17/17/">Page-17</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/18/18/">Page-18</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/19/19/">Page-19</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/20/20/">Page-20</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/21/21/">Page-21</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/22/22/">Page-22</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/23/23/">Page-23</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/24/24/">Page-24</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/25/25/">Page-25</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/26/26/">Page-26</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/27/27/">Page-27</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/28/28/">Page-28</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/29/29/">Page-29</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/30/30/">Page-30</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/31/31/">Page-31</a></LI> <LI><a href="http://www.mzines.net/publication/297/wqtaigylu/32/32/">Back-Cover</a></LI> <LI><a href="http://www.mzines.net/publications/297/x/sitemap.xml" target="_blank">site map</a></LI> </UL>

 

If you would like to view publication without flash plugin, please click on link below




To view your publication, you need to upgrade your Flash Player

Click here to install latest flash player.